Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics

Rhea-AI Summary

Tempus AI, Inc. (NASDAQ: TEM) has expanded its collaboration with Remix Therapeutics, a clinical-stage biotech company. This partnership now includes:

1. Licensing of de-identified data cohorts
2. Use of Tempus' Lens data analytics platform for studying Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia (AML)
3. Next-generation sequencing support for Remix's Phase I trial of REM-422, an oral mRNA degrader
4. Utilization of Tempus' xT and xR assays for DNA and RNA data
5. Tracking treatment response using xM Monitor, Tempus' ctDNA assay

This expanded collaboration aims to accelerate Remix's research and development goals, particularly in advancing REM-422 into clinical trials.

Positive

• Expanded collaboration with Remix Therapeutics, potentially increasing revenue streams
• Utilization of multiple Tempus products (Lens, xT, xR, xM Monitor) in the collaboration
• Support for Remix's Phase I clinical trial, demonstrating practical application of Tempus' technology

Negative

• None.

Insights

Biotechnology Analyst

The expanded collaboration between Tempus and Remix Therapeutics marks a significant development in the field of precision medicine and RNA-targeted therapies. This partnership leverages Tempus' advanced AI-driven data analytics and sequencing capabilities to support Remix's innovative approach to drug development.

Key points to consider:

• Remix is utilizing Tempus' Lens platform to analyze specific cohorts, including Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia (AML). This targeted approach could accelerate the identification of potential drug targets and biomarkers.
• The collaboration now includes next-generation sequencing support for Remix's Phase I trial of REM-422, an oral small molecule mRNA degrader. This expansion into clinical trials signifies progress in Remix's pipeline and could potentially lead to valuable data on the efficacy of their novel approach.
• Tempus' xT, xR and xM Monitor assays are being employed to capture DNA and RNA data, as well as track treatment response through ctDNA analysis. This comprehensive molecular profiling could provide important insights into drug mechanism and patient response, potentially streamlining the drug development process.

For investors, this collaboration underscores the growing importance of AI and big data in drug discovery and development. It also highlights Tempus' ability to attract partnerships with innovative biotechs, potentially driving revenue growth and expanding its footprint in the precision medicine market. However, it's important to note that early-stage drug development carries inherent risks and the success of this collaboration will ultimately depend on the clinical outcomes of Remix's pipeline.

Financial Analyst

The expanded collaboration between Tempus and Remix Therapeutics presents several financial implications for Tempus:

• Revenue Diversification: By providing a range of services including data licensing, analytics and sequencing support, Tempus is diversifying its revenue streams within the collaboration. This multi-faceted approach could lead to more stable and potentially higher revenue from each partnership.
• Market Position: The expansion of an existing collaboration demonstrates Tempus' ability to upsell and grow relationships with clients. This could be viewed as a positive indicator of the company's competitive position and the value of its offerings in the market.
• Long-term Growth Potential: Supporting early-stage clinical trials, such as Remix's Phase I trial for REM-422, positions Tempus to benefit from long-term partnerships as these therapies progress through clinical development. If successful, this could lead to expanded collaborations and increased demand for Tempus' services.

While specific financial terms were not disclosed, investors should monitor for potential impacts on Tempus' revenue growth and profit margins in future quarterly reports. The collaboration's success could also influence Tempus' ability to secure similar partnerships, potentially driving further growth in its biopharma services segment.

It's worth noting that as a newly public company (NASDAQ: TEM), Tempus is still establishing its track record in the public markets. Partnerships like this one with Remix could play a important role in demonstrating the company's value proposition and growth potential to investors.

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced an expanded collaboration with Remix Therapeutics, a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease. The collaboration between Remix and Tempus began with the licensing of specific, de-identified data cohorts and has since expanded into a broader, strategic alliance.

Remix is leveraging Tempus’ multimodal data to interrogate specific cohorts, including Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia (AML) with Tempus’ data analytics platform, Lens. The newly expanded scope of work also includes next-generation sequencing support for Remix’s Phase I trial for REM-422, the company’s potent, selective, oral small molecule messenger RNA (mRNA) degrader.

To support its research, Remix is utilizing Tempus’ xT and xR assays to capture DNA and RNA data, as well as tracking treatment response on an exploratory research basis with xM Monitor, the company’s circulating tumor DNA (ctDNA) assay, which detects and monitors changes in circulating tumor fraction to determine response to therapy for patients with advanced cancers.

“We’re excited to work with a biotech like Remix that understands and embraces the value that Tempus’ multimodal data can bring to their important work,” said Ryan Fukushima, Chief Operating Officer of Tempus. “We were able to quickly expand our collaboration and provide Remix with an array of our offerings that are uniquely positioned to support them in achieving their research and development goals.”

“Tempus’ multimodal data, analytics, and sequencing support will be invaluable tools as we advance our lead candidate, REM-422, into the clinic,” said Dominic Reynolds, Ph.D., Chief Scientific Officer of Remix. “This collaboration provides us with robust resources and data to propel our research forward, ultimately advancing our goal of creating meaningful new treatment options for patients.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Final Prospectus filed with the Securities and Exchange Commission (“SEC”) on June 17, 2024, pursuant to Rule 424(b)(4) under the Securities Act, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240730882238/en/

Erin Carron

media@tempus.com

Source: Tempus AI, Inc.

FAQ

What is the purpose of Tempus AI's expanded collaboration with Remix Therapeutics?

The expanded collaboration aims to support Remix Therapeutics' research and development goals, particularly in advancing their lead candidate REM-422 into clinical trials. Tempus is providing data analytics, next-generation sequencing support, and various assays to aid in Remix's studies of specific cancer types and treatment responses.

Which Tempus (TEM) products are being used in the collaboration with Remix Therapeutics?

Tempus is providing several products in this collaboration, including their Lens data analytics platform, xT and xR assays for DNA and RNA data, and xM Monitor, a ctDNA assay for tracking treatment response in advanced cancers.

What specific cancer types is Remix Therapeutics studying using Tempus (TEM) data?

Remix Therapeutics is using Tempus' data to study specific cohorts, including Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia (AML).

How is Tempus (TEM) supporting Remix Therapeutics' Phase I trial for REM-422?

Tempus is providing next-generation sequencing support for Remix's Phase I trial of REM-422, which is a potent, selective, oral small molecule messenger RNA (mRNA) degrader.